Myeloma | Tumor

CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.

FDA Grants Priority Review to Darzalex Combo for Multiple Myeloma

May 31st 2019

The Food and Drug Administration granted a priority review to Darzalex in combination with Velcade (bortezomib), thalidomide and dexamethasone, also known as Vtd, for the front-line treatment of newly diagnosed patients with multiple myeloma.

FDA Approves Jakafi for the Treatment of Patients with Acute Graft-Versus-Host Disease

May 24th 2019

The FDA has approved Jakafi, the first and only treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients aged 12 years and older.

Friday Frontline: May 24, 2019

May 24th 2019

From World Blood Cancer Day to today’s top performers fundraising for lifesaving research, here’s what’s making headlines in the cancer space this week.

Revlimid Reduces Risk of Smoldering Multiple Myeloma Progressing Into Cancer

May 20th 2019

Using Revlimid as a preventative treatment for smoldering multiple myeloma significantly reduced the risk for the precursor disease to progress into cancer, compared with just observation.

CAR-T Cell Therapy Shows Promise in Early Trial Among Patients with Multiple Myeloma

May 8th 2019

Treatment with bb2121 showed promising efficacy and safety among heavily pretreated patients with multiple myeloma, according to interim results published in the New England Journal of Medicine.

Survey Shows Split Between Blood Cancer Detection: Symptom Evaluation vs. Incidental Finding

April 30th 2019

Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.

CAR-T Cells Could Play a Vital Role in Multiple Myeloma Treatment

April 6th 2019

An expert discusses how CAR-T cells will fit into the treatment paradigm for patients with multiple myeloma in the future.

Allogeneic HSCT Shows Curative Potential in Relapsed Multiple Myeloma

April 5th 2019

Although a reasonable and often curative treatment option, use of allogeneic hematopoietic stem cell therapy in relapsed multiple myeloma still tends to fall under the radar.

New Therapies Offer a Brighter Future for Multiple Myeloma

April 4th 2019

An expert discusses treating multiple myeloma with potential curative intent.

FDA Advisory Committee Votes Against Accelerated Approval of Selinexor for Multiple Myeloma

February 27th 2019

The Oncologic Drugs Advisory Committee (ODAC) voted 8 to 5 recommending the FDA delay approval of selinexor for the treatment of patients with penta-refractory multiple myeloma until further trial data are available.

Topline Results Support Quicker, Convenient Administration of Darzalex in Myeloma Therapy

February 27th 2019

Outcomes associated with subcutaneous injections of Darzalex (daratumumab) appeared similar to IV administration in patients with relapsed or refractory myeloma, according to the phase 3 COLUMBA trial.

Power in Numbers

February 13th 2019

Patients with multiple myeloma find relief from side effects, thanks to newer drug combinations.

Uncovering the Enemy Within

February 13th 2019

Researchers are using innovative technology to hunt down hidden cancer cells.

FDA Approves Split Darzalex Dosing Regimen for Myeloma Treatment

February 12th 2019

The Food and Drug Administration (FDA) approved a split-dosing regimen for Darzalex (daratumumab) for the treatment of patients with multiple myeloma.

Increasing Myeloma and Other Cancer Incidence in Younger Adults Points to Obesity Epidemic

February 7th 2019

Obesity may be to blame for increasing rates of certain cancers in young adults.

Split Dosing Has Comparable Results in Myeloma Treatment

February 5th 2019

Splitting up Darzalex dosing had comparable results to standard dosing schedules in patients with myeloma.

Friday Frontline: Feb. 1, 2019

February 1st 2019

From World Cancer Day to top performers and athletes, here is a quick overview of what is making headlines in the cancer space.

Multiple Myeloma: Know the Basics

January 17th 2019

Multiple myeloma is a type of blood cancer that originates in the bones. Here’s what you need to know about the disease.

Oral Chemo Makes the Prospect of Facing a Lifelong Cancer Prognosis That Much Easier

January 13th 2019

All in all, I’m very pleased with being able to get my oral chemo directly from my clinic’s pharmacy. The staff knows me and they know my doctor.

A Brighter Future for Blood Cancers

January 7th 2019

Toronto’s Jeff Lipton, PhD, MD, FRCPC, shares his thoughts on the outlook for blood cancers.

Cord Blood Transplantation Provides 'Donor for Every Patient'

January 5th 2019

In an interview with CURE, Filippo Milano, M.D., Ph.D., explains what cord blood transplantation is and why it is important for patients to learn more.

Increased Drug Dosage Could Improve Survival in Myeloma

December 19th 2018

Patients with myeloma who took higher doses of Kyprolis plus dexamethasone tended to have better survival outcomes, according to a recent study.

Darzalex Shows Potential as New Standard of Care in Newly Diagnosed Patients with Myeloma

December 13th 2018

The combination of Darzalex (daratumumab), Revlimid (lenalidomide) and dexamethasone significantly reduced the risk for disease progression in patients with newly diagnosed multiple myeloma.

Myeloma Takeaways from the GRIFFIN Trial

December 11th 2018

New findings could spark change in the way that some patients with multiple myeloma are treated.

Myeloma Treatment: Then and Now

December 9th 2018

Take a look at content from CURE Magazine from 10 years ago to see how the myeloma space – and our magazine in general – has changed!

Myeloma Outcomes of Black Veterans Differ from Non-Veterans

December 9th 2018

In the general population, African Americans tend to have poorer myeloma outcomes; however, that may not be the case for veterans.

Advice for Patients: Navigating the Cost of Cancer

November 16th 2018

Hear patient-to-patient advice on navigating the complicated landscape of cancer care (and its costs).

Moving Mountains to Find a Cure

November 9th 2018

"In the midst of all of the difficulty of trying to deal with something this terrible, having that hope in your back pocket is invaluable to my life and to my family." - Brian Smith, on living with multiple myeloma and participating in Moving Mountains for Multiple Myeloma's recent Iceland trek.

FDA Approves Empliciti Regimen to Treat Relapsed or Refractory Myeloma

November 7th 2018

The Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, also known as EPd, for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor.

When Clinical Trials Try Patients' Patience

November 1st 2018

Treating people with cancer requires the coordination of complex care, and adding a clinical trial to the mix can pose more challenges.